ACU-D1Alternative Names: ACUD1
Latest Information Update: 03 Dec 2015
At a glance
- Originator Emory University
- Developer Accuitis; Emory University; Mercer University
- Mechanism of Action Interleukin 6 inhibitors; Proteasome inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Psoriasis; Rosacea